Yes. Health Canada judges safety and efficacy; CDR judges on cost-effectiveness. They also go back over the effectiveness, which is not their job. The answer to your question on whether they enhance access to the drugs is no. It is quite the contrary. They turn down two-thirds of the drugs for funding.
On April 30th, 2007. See this statement in context.